Pentraxin 3/sLOX-1 as a markar for early diagnosis of coronary artery abnormality in Kawasaki Disease

Pentraxin 3/sLOX-1 as a markar for early diagnosis of coronary artery abnormality in Kawasaki Disease - PTX3/sLOX-1 in Kawasaki Disease with coronary artery abnormality

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009532

Enrollment

100

Registered

2013-01-01

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Suspected of Kawasaki Disease KD Principal symptoms 1. Fever persisting 5 days or more; inclusive of cases in whom the fever has subsided before the fifth day in response to therapy; 2. Bilateral conjunctival congestion; 3. Changes of lips and oral cavity; reddening of lips, strawberry tongue, diffuse injection of oral and haryngeal mucosa; 4. Polymorphous exanthema; 5. Changes of peripheral extremities; 6. Acute non-purulent cervical lymphadenopathy. At least five items of 6 should be satisfied for diagnosis of KD. However, patients with four items of the principal symptoms can be diagnosed with KD when coronary aneurysm or dilatation is recognized by 2-D echocardiography or coronary angiography. The atypical; incomplete or suspected cases of KD is clincally important since they often develop coronary artery abnormalities. Approximately 10% of the total cases do not fulfil five of the six principal symptoms, in which other diseases can be excluded and KD is suspected. In some of these patients, coronary artery aneurysms have been confirmed. The prevalence of coronary artery abnormalities among those atypical patients was 5.5%.

Exclusion criteria

Exclusion criteria: If Kawasaki Disease has been excluded

Design outcomes

Primary

Measure	Time frame
high value of plasma PTX3/sLOX-1 in KD patients with coronary artery abnormality	—

Secondary

Measure	Time frame
not high value of plasma PTX3/sLOX-1 in KD patients without coronary artery abnormality at any sample point; onset, before IVIG therapy, after IVIG, near discharge, after discharge.	—

Countries

Japan

Contacts

Public ContactToshiyuki Kitoh

Aichi Medical University Hospital Pediatrics

tkitoh@aichi-med-u.ac.jp0561-62-3311

Outcome results